Urethritis

Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted InfectionMISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that Labquality Ltd., a collaborator and customer, is presenting results of its use of Microbix Quality Assessment Products (“QAPs™”) for accreditation of clinical labs for conducting molecular (“MDx”) tests for antimicrobial-resistant (“AMR”) strains of M. genitalium (“Mgen”), a common sexually-transmitted infection (“STI”). The poster presentation of results will be made at ECCMID 2024, the European Congress of Clinical Microbiology and Infectious Diseases taking place in Barcelona, Spain from April 27 to 30, 2024. The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix. Mgen is a common STI in both men and women who have been sexually-active. Left untreated, Mgen is known to cause chronic health problems in women, such as chronic pain, ectopic pregnancy, infertility, and pelvic inflammatory disease, and non-gonococcal urethritis in men. As many as 50% of Mgen infections can be resistant to first-line antibiotic treatments. Tests for Mgen were not commonly conducted until the past several years, in part due to the unavailability of controls (e.g., QAPs) to assess and validate the accuracy of tests for antibiotic-susceptible and AMR strains of this bacteria. As testing for Mgen and AMR Mgen infections becomes more widespread, external quality assessment (“EQA”) programs are needed to evaluate the proficiency of clinical labs and provide them accreditation to test patient-samples. The poster presents results of a Labquality program evaluating the proficiency of 38 clinical labs in their use of 16 different MDx assays (12 commercial & 4 lab-developed). Each clinical lab was evaluated for its ability to detect (i) Mgen, and (ii) an Mgen-related marker of resistance to macrolide antibiotics. It was found that (i) the Microbix Mgen QAPs (positives & negatives) were well-suited for this usage, (ii) the performance of labs and assays was excellent, (iii) specific reporting guidelines are needed to avoid errors, and (iv) there is a need for such an EQA program to support Mgen testing. Microbix developed its Mgen QAPs to resemble patient specimens, support the whole testing process, and contain all possible MDx test targets – buffered and desiccated onto a Copan® FLOQSwab® to ensure multi-year product stability at room temperature. The pilot EQA program confirmed the performance of these QAPs across all clinical labs, instrument platforms, and assays. These Mgen QAPs are now available from Microbix as part of its PROCEEDx®FLOQ® (RUO) or REDx™FLOQ® (IVD) catalogue of products. Enquiries regarding the EQA program being developed by Labquality to qualify and support clinical laboratories in molecular testing for Mgen and AMR Mgen should be directed to Ms. Kati Luiro, EQA Coordinator, at kati.luiro@labquality.com, info@labquality.com, or via its website www.labquality.com. Purchase enquiries for these or other Microbix QAPs can be e-mailed to customer.service@microbix.com. About Microbix Biosystems Inc.Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and annualized revenues approaching C$ 2.0 million per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking InformationThis news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of Labquality or its EQA schemes, the Poster, the Mgen QAPs, or their relevance, Microbix’s or others’ products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix’s judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit https://microbix.com or https://www.sedarplus.ca for recent Microbix news and filings. For further information, please contact Microbix at: Cameron Groome, CEO(905) 361-8910Jim Currie, CFO(905) 361-8910Deborah Honig, Investor RelationsAdelaide Capital Markets(647) 203-8793 ir@microbix.com Copyright © 2024 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, PROCEEDx®, QAPs™, and REDx™ are trademarks of Microbix Biosystems Inc.PROCEEDx®FLOQ® and REDx™FLOQ® are trademarks of Microbix Biosystems Inc. in collaboration with Copan Italia S.p.A.Copan®, FLOQ®, and FLOQSwab® are trademarks of Copan Italia S.p.A.Other companies’ names and products are protected by their respective trademarks.

DUBLIN, Sept. 1, 2022 /PRNewswire/ -- The 'Global Urinary Tract Infection Testing Market Size, Share & Trends Analysis by Type (Urethritis, Cystitis, Pyelonephritis), by End-Use (Reference Laboratories, General Practitioners, Urologists, Urgent Care), by Region, and Segment Forecasts, 2022-2030' report has been added to ResearchAndMarkets.com's offering. The global urinary tract infection testing market is expected to reach USD 765.6 million by 2030. The UTI testing market is witnessing growth due to factors such as rising disease burden, increasing geriatric population, rapid technological advancements, and high R&D investments by key players to introduce novel & innovative products, such as self-testing & rapid Point-of-Care (PoC) devices products. Urinary tract infection is becoming a common global concern. According to research studies, UTI occurs in one in five adult women at some point in their life. In the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. In the U.S., about 250,000 cases of pyelonephritis are reported every year. In women aged 18-19, its incidence is about 28/10,000, out of which 7% of cases require hospital admission. Genetic and cultural factors may influence its prevalence; for instance, in South Korea, the incidence of pyelonephritis is around 59/10,000. Its recurrence is more common than other UTIs, with the recurrence rate being 5.7% in men and 9% in women. Patients with diabetes are at increased risk of developing urinary tract infections such as acute cystitis, and therefore, the increasing global prevalence of diabetes is likely to contribute to cystitis growth. According to an NCBI article, type 2 diabetes raises UTI risk and patients with type 2 diabetes experience frequent & severe UTIs. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. Moreover, the estimated prevalence of asymptomatic bacteriuria in diabetic females is 26%, compared to 6% in nondiabetic females. Such factors are expected to boost the prevalence of cystitis globally. However, due to the rise in awareness about such diseases, the demand for specialist treatment has increased in recent years. According to the U.S. Department of Health and Human Services, in the U.S., the number of practicing urologists in 2020 was 4.07 per 100,000 populations. The report further stated that due to the rise in demand, a shortage of urologists was observed, which is likely to exceed nearly 3,600 physicians by 2025. This can impede market growth in the coming years. Moreover, COVID-19 has had a detrimental impact on the industry. Individuals with UTIs have experienced substantial disruptions in testing and emergency care. Key players are introducing novel products to strengthen their portfolios. For instance, in September 2021, OpGen, Inc. announced initiating clinical trials of the Unyvero Urinary Tract Infection Panel. The panel can analyze a broad range of pathogens and antimicrobial resistance markers directly from a urine sample. Successful clinical trials and the launch of such technologically advanced & efficient products are anticipated to drive market growth over the coming years. Similarly, in July 2020, Uqora, Inc. (Pharmavite, LLC), a urinary health biotechnology company, launched a UTI diagnostic and management kit. The kit includes a rapid UTI diagnostic device, Clarify, compatible with a PoC and homecare setting. Urinary Tract Infection Testing Market Highlights Cystitis dominated the market in 2021, with an estimated market share of 41.56%. This can be attributed to the high incidence & recurrence rate of cystitis, increased number of product approvals, and the high number of diabetes patients who are more prone to cystitis The general practitioner segment held a share of 12.41% in 2021. It is the primary point of contact for most patients with UTI, and in most cases, uncomplicated UTI is diagnosed and treated by a general practitioner North America dominated the overall urinary tract infection market in terms of value. This can be attributed to better reimbursement facilities and a rise in the adoption of novel diagnostic products due to increased awareness Key Topics Covered: Chapter 1 Methodology and Scope Chapter 2 Executive Summary Chapter 3 Urinary Tract Infection Market Variables, Trends, and Scope 3.1 Penetration and Growth Prospect Mapping 3.2 Regulatory Landscape 3.3 Industry Analysis - Porter's 3.4 Consumer Behavior Analysis 3.5 PESTEL Analysis (Political & Legal, Economic, and Technological) 3.6 Epidemiology Analysis 3.7 Custom Analysis Chapter 4 Urinary Tract Infection Market: Segment Analysis, by End-Use, 2017 - 2028 (USD Million) (Volume, Units) 4.1 Urinary Tract Infection Market: End-use Movement Analysis 4.2 General Practitioners 4.2.1 General practitioners Market, 2017 - 2028 (USD Million) 4.2.2 General practitioners Market, Instruments, 2017 - 2028 (USD Million) 4.2.3 General practitioners Market, Instruments, 2017 - 2028, Volume (Units) 4.2.4 General practitioners Market, Consumables, 2017 - 2028 (USD Million) 4.2.5 General practitioners Market, Consumables, 2017-2028, Volume (Thousand Units) 4.3 Urologists 4.3.1 Urologists Market, 2017 - 2028 (USD Million) 4.3.2 Urologists Market, Instruments, 2017 - 2028 (USD Million) 4.3.3 Urologists Market, Instruments, 2017 - 2028, Volume (Units) 4.3.4 Urologists Market, Consumables, 2017 - 2028 (USD Million) 4.3.5 Urologists Market, Consumables, 2017-2028, Volume (Thousand Units) 4.4 Urogynecologists 4.4.1 Urogynecologists Market, 2017 - 2028 (USD Million) 4.4.2 Urogynecologists Market, Instruments, 2017 - 2028 (USD Million) 4.4.3 Urogynecologists Market, Instruments, 2017 - 2028, Volume (Units) 4.4.4 Urogynecologists Market, Consumables, 2017 - 2028 (USD Million) 4.4.5 Urogynecologists Market, Consumables, 2017-2028, Volume (Thousand Units) 4.5 Reference Laboratories 4.5.1 Reference Laboratories Market, 2017 - 2028 (USD Million) 4.5.2 Reference Laboratories Market, Instruments, 2017 - 2028 (USD Million) 4.5.3 Reference Laboratories Market, Instruments, 2017 - 2028, Volume (Units) 4.5.4 Reference Laboratories Market, Consumables, 2017 - 2028 (USD Million) 4.5.5 Reference Laboratories Market, Consumables, 2017-2028, Volume (Thousand Units) 4.6 AccounTable Care Organizations 4.7 Hospital Laboratories 4.7.1 Hospital Laboratories Market, 2017 - 2028 (USD Million) 4.7.2 Hospital Laboratories Market, Instruments, 2017 - 2028 (USD Million) 4.7.3 Hospital Laboratories Market, Instruments, 2017 - 2028, Volume (Units) 4.7.4 Hospital Laboratories Market, Consumables, 2017 - 2028 (USD Million) 4.7.5 Hospital Laboratories Market, Consumables, 2017-2028, Volume (Thousand Units) 4.8 Urgent Care 4.8.1 Urgent Care Market, 2017 - 2028 (USD Million) 4.8.2 Urgent Care Market, Instruments, 2017 - 2028 (USD Million) 4.8.3 Urgent Care Market, Instruments, 2017 - 2028, Volume (Units) 4.8.4 Urgent Care Market, Consumables, 2017 - 2028 (USD Million) 4.8.5 Urgent Care Market, Consumables, 2017-2028, Volume (Thousand Units) 4.9 Hospital Emergency Departments 4.9.1 Hospital Emergency Departments Market, 2017 - 2028 (USD Million) 4.9.2 Hospital Emergency Departments Market, Instruments, 2017 - 2028 (USD Million) 4.9.3 Hospital Emergency Departments Market, Instruments, 2017 - 2028, Volume (Units) 4.9.4 Hospital Emergency Departments Market, Consumables, 2017 - 2028 (USD Million) 4.9.5 Hospital Emergency Departments Market, Consumables, 2017-2028, Volume (Thousand Units) 4.10 Others 4.10.1 Others Market, 2017 - 2028 (USD Million) 4.10.2 Others Market, Instruments, 2017 - 2028 (USD Million) 4.10.3 Others Market, Instruments, 2017 - 2028, Volume (Units) 4.10.4 Others Market, Consumables, 2017 - 2028 (USD Million) 4.10.5 Others Market, Consumables, 2017-2028, Volume (Thousand Units) Chapter 5 Urinary Tract Infection Market: Segment Analysis, by Type Scope, 2017 - 2028 (USD Million) 5.1 Urinary Tract Infection Market: Type Scope Movement Analysis 5.2 Urethritis 5.2.1 Urethritis Market, 2017 - 2028 (USD Million) 5.3 Cystitis 5.3.1 Cystitis market, 2017 - 2028 (USD Million) 5.4 Pyelonephritis 5.4.1 Pyelonephritis Market, 2017 - 2028 (USD Million) Chapter 6 Urinary Tract Infection Market: Segment Analysis, By Region, 2017 - 2028 (USD Million) Chapter 7 Urinary Tract Infection Market: Competitive Analysis 7.1 Recent Developments and Impact Analysis, by Key Market Participants 7.1.1 New Product Launches 7.1.2 Mergers and Acquisitions 7.1.3 Partnerships and Strategic Collaboration 7.2 Company Categorization 7.2.1 Innovators 7.2.3 Market Leaders 7.3 Vendor Landscape 7.3.1 List of key distributors and channel partners 7.4 Key Customers 7.5 Key Company Market Share Analysis, 2020 7.6 Public Companies 7.6.1 Company market position analysis 7.6.2 Competitive Dashboard Analysis 7.6.3 Market Differentiators 7.7 Private Companies 7.7.1 List of key emerging companies 7.7.2 Regional Network Map 7.8 Company Profiles 7.8.1 QIAGEN 7.8.1.1 Company overview 7.8.1.2 Financial performance 7.8.1.3 Product benchmarking 7.8.1.4 Strategic initiatives 7.8.2 Accelerate Diagnostics, Inc. 7.8.2.1 Company overview 7.8.2.2 Financial performance 7.8.2.3 Product benchmarking 7.8.3 Bio-Rad Laboratories, Inc. 7.8.3.1 Company overview 7.8.3.2 Financial performance 7.8.3.3 Product benchmarking 7.8.4 F. Hoffmann-La Roche Ltd. 7.8.4.1 Company overview 7.8.4.2 Financial Performance 7.8.4.3 Product Benchmarking 7.8.4.4 Strategic initiatives 7.8.5 Danaher Corporation 7.8.5.1 Company overview 7.8.5.2 Beckman Coulter 7.8.5.3 Financial Performance 7.8.5.4 Product benchmarking 7.8.5.5 Strategic initiatives 7.8.6 Siemens Healthcare GmbH 7.8.6.1 Company overview 7.8.6.2 Financial performance 7.8.6.3 Product benchmarking 7.8.6.4 Strategic initiatives 7.8.7 Randox Laboratories Ltd. 7.8.7.1 Company overview 7.8.7.2 Product benchmarking 7.8.8 Thermo Fisher Scientific, Inc. 7.8.8.1 Company overview 7.8.8.2 Financial performance 7.8.8.3 Product benchmarking 7.8.8.4 Strategic initiatives 7.8.9 bioMerieux SA 7.8.9.1 Company overview 7.8.9.2 Financial performance 7.8.9.3 Product benchmarking 7.8.9.4 Strategic initiatives 7.8.10 T2 Biosystems, Inc. 7.8.10.1 Company overview 7.8.10.2 Financial performance 7.8.10.3 Product benchmarking 7.8.10.4 Strategic initiatives For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Prostate stents are medical devices used to keep open the space surrounding prostatic urethra and bladder neck in order to allow smooth urine flow in case of urine incontinence. These stents are effective in alleviating the bladder outlet obstruction resulted from benign prostatic hyperplasia (common among men aged above 70 years). However, a prostate stent should not be positioned too proximal to the external sphincter because it could cause urine incontinence. Other complications caused by prostate stents include risk of formation of bladder stones and granulation tissues. Additional formation of tissue surrounding the stent could obstruct the normal urine flow. Request Brochure of Report - According to Scientific Reports, the global prevalence of benign prostatic hyperplasia was estimated at 26% in 2017 and it increases with age. The global prostate stents market is primarily driven by increase in cases of benign prostatic hyperplasia, diagnosis and treatment rates among men, preference for minimally invasive surgery, health care infrastructure, availability of prostate stents, and presence of major players. Stringent regulatory landscape and product recalls are likely to hamper the growth of the global prostate stents market during the forecast period. However, mergers and acquisitions among major players, increase in R&D investments by key manufacturers, and technological advancements are projected to drive the global prostate stents market in the next few years. In terms of material type, the global prostate stents market can be segmented into metal, plastic, and others. Metal stents have significant advantages in the urology field. The risk of urethral injury is low when a metal stent is inserted by compressing it through the urethra. Based on product type, the global prostate stents market can be bifurcated into permanent and temporary. Several studies have indicated that the use of permanent stents causes migration of stents and recurrence of urinary tract infections. Development of plastic stents could eliminate the problem of stent migration. Request for Analysis of COVID-19 Impact on Prostate Stents Market – In terms of end-user, the global prostate stents market can be divided into hospitals, clinics, and others. The hospitals segment held the largest market share in 2017. The others segment includes home care and academic & research institutes. Geographically, the global prostate stents market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to the American Urological Association, benign prostatic hyperplasia is a common urologic abnormality in the U.S. and its incidence increases with age. North America held the largest share of the global prostate stents market in 2017, owing to significant incidence of benign prostatic hyperplasia among men, high diagnostic and treatment rates of benign prostatic hyperplasic, robust health care infrastructure, availability of health care re-imbursement for treatment of urological diseases in the U.S., presence of major players, and availability of prostate stents. Europe held the second largest market share in 2017 due to higher awareness about the outcomes of benign prostatic hyperplasia, presence of major companies, and availability of prostate stents. A study published in the World Journal of Urology in 2015 stated that older men in Europe with higher education, access to health care, and involved in medical services are more likely to self-report being diagnosed. Developing health care infrastructure, larger patient population, intense competition between domestic players and global players, and technological advancements are projected to drive the prostate stents market in Asia Pacific. High cost of prostate stents and underdeveloped health care infrastructure in Latin America and Middle East & Africa are likely to restrain the prostate stents market during the forecast period. Pre book Prostate Stents Market Report at Major companies in the global prostate stents market are SRS Medical, Pnn Medical A/S, Boston Scientific, Allium Medical, and C. R. Bard (part of BD), among others. Top of Form Read More Information: About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: